VCYT:NSD-Veracyte Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 42.11

Change

+1.69 (+4.18)%

Market Cap

USD 0.21B

Volume

0.88M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte Inc is engaged in the discovery, development and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+1.87 (+0.41%)

USD 34.56B
NTRA Natera Inc

-4.42 (-2.56%)

USD 23.36B
ILMN Illumina Inc

-5.80 (-5.63%)

USD 21.05B
ICLR ICON PLC

+10.52 (+5.50%)

USD 16.55B
MEDP Medpace Holdings Inc

+0.89 (+0.26%)

USD 10.85B
EXAS EXACT Sciences Corporation

-0.97 (-1.92%)

USD 9.13B
GH Guardant Health Inc

-1.60 (-3.27%)

USD 5.49B
RDNT RadNet Inc

-1.64 (-2.55%)

USD 4.54B
SHC Sotera Health Co

-0.11 (-0.81%)

USD 3.91B
TWST Twist Bioscience Corp

-2.90 (-6.04%)

USD 3.12B

ETFs Containing VCYT

GNOG:LSE Global X Genomics & Biote.. 5.67 % 0.00 %

-0.08 (-5.90%)

USD 9.83M
GN0M:XETRA 5.34 % 0.00 %

N/A

N/A
GNOM:SW Global X Genomics & Biote.. 5.34 % 0.00 %

-0.06 (-5.90%)

USD 9.83M
ARCG:LSE ARK Genomic Revolution UC.. 4.42 % 0.00 %

-28.50 (-5.90%)

USD 5.84M
ARKG:LSE ARK Genomic Revolution UC.. 4.42 % 0.00 %

-0.33 (-5.90%)

USD 5.84M
EDOC:LSE Global X Telemedicine & D.. 4.11 % 0.00 %

-0.18 (-5.90%)

USD 2.72M
EDOG:LSE Global X Telemedicine & D.. 4.11 % 0.00 %

-0.22 (-5.90%)

USD 0.16M
DDOC:F 4.08 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.66 % 0.00 %

-18.90 (-5.90%)

USD 3.82M
WDNA WisdomTree BioRevolution .. 2.58 % 0.00 %

-0.16 (-5.90%)

USD 2.27M
WRNA:XETRA 2.53 % 0.00 %

N/A

N/A
ETHO Amplify ETF Trust 0.00 % 0.45 %

-0.44 (-5.90%)

USD 0.18B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.13 (-5.90%)

USD 0.07B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.16 (-5.90%)

USD 0.04B
DDOC:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.34% 64% D 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.34% 64% D 68% D+
Trailing 12 Months  
Capital Gain 71.60% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.60% 81% B- 88% B+
Trailing 5 Years  
Capital Gain 66.84% 90% A- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.84% 90% A- 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.61% 57% F 56% F
Dividend Return 6.61% 55% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.94% 63% D 39% F
Risk Adjusted Return 13.50% 61% D- 45% F
Market Capitalization 0.21B 78% C+ 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 2.90 43% 38%
Price / Cash Flow Ratio 76.78 2% 4%
Price/Free Cash Flow Ratio 183.35 5% 2%
Management Effectiveness  
Return on Equity -0.83% 84% 57%
Return on Invested Capital -7.89% 74% 42%
Return on Assets 1.07% 84% 67%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector